These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8327652)

  • 1. The heparin target organ--the endothelium. Studies in a rat model.
    Hiebert LM; Wice SM; McDuffie NM; Jaques LB
    Q J Med; 1993 May; 86(5):341-8. PubMed ID: 8327652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral heparins.
    Hiebert LM
    Clin Lab; 2002; 48(3-4):111-6. PubMed ID: 11934211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for the absorption of heparin by rat stomach.
    Hiebert LM; Wice SM; Abdelhameed T
    Biomed Pharmacother; 2007 Jan; 61(1):68-74. PubMed ID: 17196786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in rats.
    Costantini V; Deveglia R; Stabile A; Nenci GG
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):7-13. PubMed ID: 10691095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution and antithrombotic activity of unlabeled or 14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route.
    Hiebert LM; Wice SM; Ping T; Hileman RE; Capila I; Linhardt RJ
    Can J Physiol Pharmacol; 2000 Apr; 78(4):307-20. PubMed ID: 10772058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000.
    Jaques LB; Hiebert LM; Wice SM
    J Lab Clin Med; 1991 Feb; 117(2):122-30. PubMed ID: 1993853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.
    Hiebert LM; Wice SM; Ping T; Herr D; Laux V
    Thromb Haemost; 2001 Jan; 85(1):114-8. PubMed ID: 11204561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
    Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The internalization and release of heparins by cultured endothelial cells: the process is cell source, heparin source, time and concentration dependent.
    Hiebert LM; McDuffie NM
    Artery; 1990; 17(2):107-18. PubMed ID: 2155600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intracellular uptake and protracted release of exogenous heparins by cultured endothelial cells.
    Hiebert LM; McDuffie NM
    Artery; 1989; 16(4):208-22. PubMed ID: 2742511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local heparin is superior to systemic heparin in preventing arterial thrombosis.
    Andresen DM; Barker JH; Hjortdal VE
    Microsurgery; 2002; 22(6):265-72. PubMed ID: 12375294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity of binding of radiolabeled (125I) heparin and low molecular weight heparin fraction CY 222 to endothelium in culture.
    Psuja P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):429-36. PubMed ID: 2444518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity].
    Jacobs C; Grebe S; Kietzmann M; Mischke R
    Dtsch Tierarztl Wochenschr; 1999 Nov; 106(11):478-81. PubMed ID: 10609418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP technical report on the toxicity studies of p-tert-butylcatechol (CAS No. 98-29-3) administered in feed to F344/N rats and B6C3F1 mice.
    Dunnick J
    Toxic Rep Ser; 2002 Nov; (70):5-51. PubMed ID: 12592414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
    Daykin HJ; Sturgeon SA; Jones C; Wright CE
    Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial sequestration of heparin administered by the intrapulmonary route.
    Mahadoo J; Hiebert LM; Jaques LB; Wright CJ
    Artery; 1980; 7(5):438-47. PubMed ID: 7213028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.